Research areas
Novo Nordisk CEO Warns of Growing Competition in Obesity Drug Market
Novo Nordisk's CEO believes investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will prevent the market from becoming a winner-take-all battle with rival Eli Lilly.